Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters

Language
Document Type
Year range
1.
ACS Pharmacol Transl Sci ; 5(7): 468-478, 2022 Jul 08.
Article in English | MEDLINE | ID: covidwho-1908096

ABSTRACT

The COVID-19 pandemic has had enormous health, economic, and social consequences. Vaccines have been successful in reducing rates of infection and hospitalization, but there is still a need for acute treatment of the disease. We investigate whether compounds that bind the human angiotensin-converting enzyme 2 (ACE2) protein can decrease SARS-CoV-2 replication without impacting ACE2's natural enzymatic function. Initial screening of a diversity library resulted in hit compounds active in an ACE2-binding assay, which showed little inhibition of ACE2 enzymatic activity (116 actives, success rate ∼4%), suggesting they were allosteric binders. Subsequent application of in silico techniques boosted success rates to ∼14% and resulted in 73 novel confirmed ACE2 binders with K d values as low as 6 nM. A subsequent SARS-CoV-2 assay revealed that five of these compounds inhibit the viral life cycle in human cells. Further effort is required to completely elucidate the antiviral mechanism of these ACE2-binders, but they present a valuable starting point for both the development of acute treatments for COVID-19 and research into the host-directed therapy.

2.
ACS Pharmacol Transl Sci ; 4(5): 1675-1688, 2021 Oct 08.
Article in English | MEDLINE | ID: covidwho-1450269

ABSTRACT

The National Center for Advancing Translational Sciences (NCATS) has been actively generating SARS-CoV-2 high-throughput screening data and disseminates it through the OpenData Portal (https://opendata.ncats.nih.gov/covid19/). Here, we provide a hybrid approach that utilizes NCATS screening data from the SARS-CoV-2 cytopathic effect reduction assay to build predictive models, using both machine learning and pharmacophore-based modeling. Optimized models were used to perform two iterative rounds of virtual screening to predict small molecules active against SARS-CoV-2. Experimental testing with live virus provided 100 (∼16% of predicted hits) active compounds (efficacy > 30%, IC50 ≤ 15 µM). Systematic clustering analysis of active compounds revealed three promising chemotypes which have not been previously identified as inhibitors of SARS-CoV-2 infection. Further investigation resulted in the identification of allosteric binders to host receptor angiotensin-converting enzyme 2; these compounds were then shown to inhibit the entry of pseudoparticles bearing spike protein of wild-type SARS-CoV-2, as well as South African B.1.351 and UK B.1.1.7 variants.

3.
ACS Pharmacol Transl Sci ; 4(3): 1124-1135, 2021 Jun 11.
Article in English | MEDLINE | ID: covidwho-1233687

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has prompted researchers to pivot their efforts to finding antiviral compounds and vaccines. In this study, we focused on the human host cell transmembrane protease serine 2 (TMPRSS2), which plays an important role in the viral life cycle by cleaving the spike protein to initiate membrane fusion. TMPRSS2 is an attractive target and has received attention for the development of drugs against SARS and Middle East respiratory syndrome. Starting with comparative structural modeling and a binding model analysis, we developed an efficient pharmacophore-based approach and applied a large-scale in silico database screening for small-molecule inhibitors against TMPRSS2. The hits were evaluated in the TMPRSS2 biochemical assay and the SARS-CoV-2 pseudotyped particle entry assay. A number of novel inhibitors were identified, providing starting points for the further development of drug candidates for the treatment of coronavirus disease 2019.

4.
Annals of Data Science ; 8(1):1-19, 2021.
Article in English | ProQuest Central | ID: covidwho-1064667

ABSTRACT

The Coronavirus Disease-2019 (COVID-19) pandemic persists to have a mortifying impact on the health and well-being of the global population. A continued rise in the number of patients testing positive for COVID-19 has created a lot of stress on governing bodies across the globe and they are finding it difficult to tackle the situation. We have developed an outbreak prediction system for COVID-19 for the top 10 highly and densely populated countries. The proposed prediction models forecast the count of new cases likely to arise for successive 5 days using 9 different machine learning algorithms. A set of models for predicting the rise in new cases, having an average accuracy of 87.9%  ± 3.9% was developed for 10 high population and high density countries. The highest accuracy of 99.93% was achieved for Ethiopia using Auto-Regressive Moving Average (ARMA) averaged over the next 5 days. The proposed prediction models used by us can help stakeholders to be prepared in advance for any sudden rise in outbreak to ensure optimal management of available resources.

SELECTION OF CITATIONS
SEARCH DETAIL